SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: CDC signage at its headquarters in Georg
CDC
CDC Adopts ACIP Recommendations on Chickenpox, COVID-19 Vaccines
A new group of CDC advisors voted last month to separate the chickenpox vaccine from the measles, mumps, rubella components of the MMRV shot due to concerns over febrile seizures, while recommending a more risk-based approach to COVID-19 immunizations that mirrors recent FDA approvals.
October 6, 2025
 · 
1 min read
 · 
Heather McKenzie
Traffic light silhouette and golden sky.
ALS
FDA Lifts Clinical Hold, Clearing Neurizon’s ALS Drug for Human Trials
The hold was placed earlier this year when the FDA asked for more preclinical data, but the agency was slow to respond due to ‘strain’ on its capacity, according to Neurizon.
October 6, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Facade of AstraZeneca's office in Shanghai, China
Artificial intelligence
AstraZeneca Makes Another AI Deal With $555M Algen Alliance
AstraZeneca has invested heavily in AI, primarily through collaborations, including an up to $5.3 billion partnership with China’s CSPC Pharmaceutical in June.
October 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Manufacturing
FDA Continues US Manufacturing Drive With Domestic Generics Pilot
This latest FDA program aims to provide speedier reviews for generic drugmakers who produce their products in the U.S.
October 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Space rocket crashed and on fire. Business failure, failed startup. Downfall of ambitious plans, flawed execution, or crisis outcomes. Volatility of startups, financial risks, or unexpected setbacks.
Gene therapy
Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy
Rocket Pharmaceuticals’ strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was developing for Fanconi anemia.
October 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Mergers & acquisitions
Chiesi, Arbor Weave $2.1B Rare Disease Pact
The centerpiece of the collaboration is the gene editor ABO-101, being developed for primary hyperoxaluria type 1, a rare disease that leads to severe kidney stones.
October 6, 2025
 · 
1 min read
 · 
Tristan Manalac
Highway in Phoenix, Arizona leading toward downtown at sunset
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
As industry leaders gather at the annual event in Phoenix, the cell and gene therapy space remains in a state of flux, with M&A activity and regulatory support signaling momentum while commercialization challenges continue to hinder broader investor interest.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
Piggy bank with life buoy isolated on blue background
Opinion
Gene Therapy’s Future Hinges on the Economics of Safety
Smarter design through targeted delivery and human-relevant testing can save the industry from costly safety failures.
October 6, 2025
 · 
7 min read
 · 
Ronald A. Li
Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS